The Gut-Brain Axis and Peptides — Larazotide, KPV, BPC-157, and VIP

What is the gut-brain axis?

The gut-brain axis is a bidirectional signaling network connecting the enteric nervous system (the gut's intrinsic 500-million-neuron nervous system, sometimes called the second brain), the vagus nerve, the hypothalamic-pituitary-adrenal axis, the immune system, and the gut microbiome — all of which communicate continuously with the central nervous system. Gut signals travel to the brain through vagal afferents, enteroendocrine cell signaling, immune mediators, and microbiome-derived metabolites. Brain signals travel to the gut through the autonomic nervous system, HPA axis hormones, and enteric nervous system modulation.

Disruption of this axis — through intestinal permeability, gut inflammation, microbiome dysbiosis, or enteric nervous system dysfunction — produces effects that extend far beyond gastrointestinal symptoms: mood disorders, cognitive impairment, immune dysregulation, and systemic inflammation all have documented gut-brain axis components. This is why gut healing peptides are increasingly studied not only for GI conditions but for their potential neurological and immune implications.

Larazotide: restoring the barrier that started it all

The gut-brain axis dysfunction cascade often begins with increased intestinal permeability — the breakdown of tight junctions between intestinal epithelial cells that allows bacterial products, undigested antigens, and endotoxins to cross into systemic circulation. Once in circulation, these luminal contents activate systemic immune responses, generate neuroinflammation via cytokine signaling across the blood-brain barrier, and produce the chronic low-grade inflammation that characterizes gut-brain axis dysfunction. Larazotide (AT-1001) addresses the upstream cause: by stabilizing intestinal tight junctions through the ZOT receptor mechanism, it restores the barrier function that prevents luminal translocation before downstream cascades develop. Phase 2 human data in celiac disease confirmed barrier restoration alongside symptom improvement — the first clinical evidence that tight junction pharmacology translates to meaningful clinical outcomes. See the Larazotide research profile.

KPV: calming mucosal immune overactivation

Once luminal translocation has occurred, mucosal immune cells — particularly mast cells and macrophages in the lamina propria — activate inflammatory responses that damage the epithelium further and generate systemic cytokine signals. KPV (lysine-proline-valine) acts through melanocortin receptors (MC1R and MC3R) on these immune cells and on intestinal epithelial cells to reduce NF-kB pathway activation and pro-inflammatory cytokine production, modulating rather than suppressing mucosal immune responses. KPV's gut-brain axis relevance extends to its effects on intestinal epithelial cell migration — promoting re-epithelialization that restores the physical barrier. Because melanocortin receptors are also expressed in the brain, some research has explored whether gut-administered KPV produces central anti-inflammatory effects through the gut-brain neuroimmune axis, though this remains early-stage. See the KPV database entry.

BPC-157: the gut healing signal with neural extensions

BPC-157 (Body Protection Compound-157) was originally isolated from human gastric juice — a fact that underscores its central role in gut biology. Its VEGFR2-driven angiogenesis repairs the vascular supply to damaged gut tissue, while ERK1/2-mediated fibroblast activity rebuilds the structural matrix of the intestinal wall. In GI research models, BPC-157 has demonstrated healing of NSAID-induced ulceration, anastomotic site repair, inflammatory bowel disease amelioration, and intestinal fistula closure. The gut-brain axis dimension of BPC-157 research extends to its neuroprotective effects: the same mechanisms that protect the gut produce neuroprotective and neuroregenerative effects when applied to neural tissue in animal models — an observation consistent with the shared evolutionary history of the enteric and central nervous systems. See the BPC-157 research profile and the oral formulation for gut-specific applications.

VIP: the neuropeptide that lives in both worlds

VIP (Vasoactive Intestinal Peptide) is perhaps the most literally gut-brain axis compound in the database — it is simultaneously a gut neuropeptide (regulating intestinal motility, secretion, and mucosal blood flow through enteric nervous system neurons) and a brain neuromodulator (synchronizing circadian rhythm through the suprachiasmatic nucleus and exerting neuroprotective effects in ischemia models). VIP is produced by neurons in both the enteric nervous system and the central nervous system, and its VPAC1 and VPAC2 receptors are expressed in both locations. In the context of the gut-brain axis, VIP's bidirectionality is mechanistically explicit: disrupted gut VIP signaling (as occurs in IBD and MCAS) affects both local gut function and the vagal and neuroendocrine signals sent to the brain. Restoring VIP signaling through the VIP peptide research protocols targets the axis at the communication node that connects the two systems rather than at either endpoint alone. See the VIP research profile.

Protocol considerations for gut-brain axis research

The Gut Healing Stack (BPC-157 oral + KPV + Larazotide) in the database addresses the gut-axis components with an all-oral protocol. For researchers interested in the full gut-brain axis — including neurological and circadian rhythm dimensions — VIP can be added via intranasal delivery for direct CNS access. BT-11 represents the newest addition, targeting the LANCL2 receptor for local gut anti-inflammatory signaling that complements KPV's melanocortin mechanism. The combined gut healing protocol library in the database covers barrier repair (Larazotide), mucosal inflammation (KPV, BT-11), tissue repair (BPC-157), and neuroimmune communication (VIP).